Epigenetics Market is segmented By Product Type (Enzymes, Kits & Assays, Reagents, Instruments), By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large noncoding RNA, MicroRNA Modification, Chromatin structures), By Application (Oncology, Non-Oncology), By End User (Academia and research, Pharmaceutical and biotechnology industry, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Epigenetics Market Size
The global epigenetics market reached USD 1,792.03 million in 2022 and is projected to witness lucrative growth by reaching up to USD 6,460.25 million by 2031. The market is growing at a CAGR of 15.3% during the forecast period (2024-2031). The field of epigenetics investigates how cells regulate gene function without altering the DNA sequence. The major global players in the market include AbClam PLC, Diagenode Inc, Active Motiff.
Epigenetic alterations to DNA control whether or not genes are activated. These alterations are connected to DNA and do not alter the order in which the DNA building blocks are arranged. The epigenome, which is all of the modifications that control how genes are expressed inside a cell's entire set of DNA, is referred to as the genome. Epigenetic modifications affect the synthesis of proteins in cells by influencing the decision of which genes are activated or inactive. Each cell only generates the proteins required for it to operate thanks to this control.
Epigenetics Market Summary
|
Metrics |
Details |
|
CAGR |
15.3% |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) and Volume (Tons) |
|
Segments Covered |
Product Type, Technology, Application, End User, and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights about the Market Request Free Sample
Epigenetics Market Dynamics
The number of people obtaining cancer diagnoses has significantly increased globally
According to the World Health Organization, cancer will be the primary cause of death for roughly 10 million people worldwide in 2020 or one in every six fatalities. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. In low- and lower-middle-income nations, cancer-causing infections, including the human papillomavirus (HPV) and hepatitis, are thought to cause 30% of cancer cases. If caught early and appropriately treated, many tumors are curable.
According to the International Agency for Research on Cancer (IARC) 2020 report, 1 in 5 individuals worldwide will develop cancer at some point in their lives, and 1 in 8 men and 1 in 11 women will pass away. According to these latest projections, more than 50 million people are alive five years after a cancer diagnosis. Globally aging populations and socioeconomic risk factors continue to be the main causes of this rise. One in four cancer diagnoses among women worldwide is breast cancer.
Expensive cost is expected to hamper the market’s growth
Epigenetic research necessitates specialised equipment and methods, which can be costly to create and keep up. The availability of epigenetic products for research and clinical application may be constrained as a result, making it challenging for smaller businesses to break into the market.
Epigenetics Market Segment Analysis
The global Epigenetics market is segmented based on product type, technology, application, end user,and region.
On basis of the end user, pharmaceutical and biotechnology industry is expected to hold the largest share
The pharmaceutical and biotechnology segment is expected to hold the largest share in the epigenetics. For instance, programs for the discovery and development of epigenetic drugs have recently received much interest and funding. The potential for developing novel treatment approaches that can successfully repair transcriptional and epigenetic aberrations prevalent in many human illnesses is what motivates this. The key income source for academic and research institutes is the rising use of epigenetics products in government research facilities and university laboratories.
It is anticipated that pharmaceutical and biotechnology companies will rapidly grow throughout the projected period. To create cutting-edge treatment methods, startups and SMEs are investing in the epigenetics industry. In November 2021, Chroma Medicine announced plans to develop an epigenetic editor that might alter how genes manufacture proteins. Funding for this startup company of USD 125 million has come from Newpath Partners, Atlas Venture, and other investors.
The startup wants to make medicines using gene-editing methods. The company wants to develop drugs that can alter the epigenome using gene-editing methods, which will be a breakthrough method of treating genetic diseases.
Source: DataM Intelligence Analysis (2023)
Global Epigenetics Market Geographical Share
Rising Product Launches and increased demandforthe Epigenetics products
North America dominates the global epigenetics market primarily due to its large population, excellent medical infrastructure, and high-income levels. Since many mammalian proteins, including growth hormones, insulin, antibodies, and vaccines, are manufactured industrially, the demand for protein expression systems is anticipated to rise along with rising spending by industries in product research and development. Additionally, there is a rising need for the creation of cancer medicines in the United States, and significant investments are being made in studying cancer genomes, which is anticipated to fuel the expansion of this market in North America.
For instance, according to the United States National Institute of Health, $1,098 million had been allocated for cancer genomics research as of December 2021. In 2022, the funding will be anticipated to total USD 1,152 million. Increased use of epigenetics in research due to increased funding for cancer genomics in the United States is anticipated to fuel market expansion over the forecast period.
In addition, the rising incidence of cancer in the U.S., the increasing need for cancer treatments, and the significant investments being made in raising awareness of cancer genetics are all expected to contribute to the market's growth in the nation. The second greatest cause of death in the nation is cancer. Around 602,350 Americans will die from cancer in the U.S. in 2020. Additionally, rising funding for cancer genomics in the United States will lead to more researchers using epigenetics in their studies, which will spur market growth throughout the forecast period.
Source: DataM Intelligence Analysis (2023)
Epigenetics Market Top Companies
The major global players in the market include AbClam PLC, Diagenode Inc, Active Motiff, Illumina Inc, New England Biolabs, Bio-Rad, Merck Millipore, QIAGEN, Thermo Fisher Inc, Siemens Healthier, and among others.
Key Developments
- On February 2022, a trial for solid tumour cancer sponsored by the National Cancer Institute (NCI), a division of the National Institutes of Health, Zenith Epigenetics Ltd. reported the administration of ZEN-3694 (a BET inhibitor) in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor OPDIVO and YERVOY on the first patient.
- On December 2021, Lonza and Agilent Technologies collaborated collectively. The goal of this collaboration is to revolutionise the process of creating customised cell treatments.
- On April 2021, The "SARS-CoV-2 Full-length Genome Sequencing" service has been introduced by Eurofins Genomics India, a top supplier of genomic goods and services. This new next-generation sequencing (NGS) service enables end-to-end monitoring of the coronavirus genome sequence and mutational drift..
Why Purchase the Report?
- To visualize the global Epigenetic- market segmentation based on type, application, end user, and region,as well as understandkey commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of Epigenetic market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global Epigenetics market report would provide approximately 61 tables,58figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
